Net profit of Astrazeneca Pharma India reported to Rs 3.22 crore in the quarter ended March 2018 as against net loss of Rs 9.56 crore during the previous quarter ended March 2017. Sales rose 30.27% to Rs 150.73 crore in the quarter ended March 2018 as against Rs 115.71 crore during the previous quarter ended March 2017.

For the full year,net profit rose 29.23% to Rs 25.91 crore in the year ended March 2018 as against Rs 20.05 crore during the previous year ended March 2017. Sales rose 5.02% to Rs 571.00 crore in the year ended March 2018 as against Rs 543.70 crore during the previous year ended March 2017.

Powered by Capital Market - Live News

The result was announced after market hours yesterday, 21 May 2018.

Meanwhile, the S&P BSE Sensex was up 87.07 points, or 0.25% to 34,703.20.

On the BSE, 2,418 shares were traded in the counter so far compared with average daily volumes of 6,049 shares in the past two weeks. The stock had hit a high of Rs 1,203.65 and a low of Rs 1,150 so far during the day. The stock hit a 52-week high of Rs 1,278 on 7 November 2017. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.

Net sales rose 30.27% to Rs 150.73 crore in Q4 March 2018 over Q4 March 2017.

AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.

Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 21 May 2018.

Powered by Capital Market - Live News

The announcement was made after market hours yesterday, 17 April 2018.

Meanwhile, the S&P BSE Sensex was up 19.61 points, or 0.06% to 34,414.67.

On the BSE, 695 shares were traded in the counter so far compared with average daily volumes of 695 shares in the past two weeks. The stock had hit a high of Rs 1,045.50 and a low of Rs 1,008.80 so far during the day. The stock hit a 52-week high of Rs 1,278 on 7 November 2017. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.

Leading global science-led biopharmaceutical company AstraZeneca announced its decision of further investing $90 million over the next 5 years in India. The announcement was made following the signature of the bilateral innovation partnership for a sustainable future between Sweden and India.

This investment commitment will span across AstraZeneca's diverse footprint in India with an aim to strengthen its manufacturing, clinical operations, patient safety & regulatory science, IT services and commercial operations. Furthermore this investment will support scientific data generation, quality manufacturing, science talent development and collaborative development of innovative solutions to improve the standard of care of non-communicable diseases in India.

Astrazeneca Pharma India reported net loss of Rs 10.35 crore in Q3 December 2017 as against net profit of Rs 16.21 crore in Q3 December 2016. Net sales declined 14.47% to Rs 128.54 crore in Q3 December 2017 over Q3 December 2016.

AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.

As on 31 December 2017, AstraZeneca Pharmaceuticals AB held 75% stake in AstraZeneca Pharma India.

Powered by Capital Market - Live News